Matches in SemOpenAlex for { <https://semopenalex.org/work/W2947305026> ?p ?o ?g. }
Showing items 1 to 100 of
100
with 100 items per page.
- W2947305026 abstract "3536 Background: FOLFOXIRI/bevacizumab is a valuable upfront option in mCRC based on results of phase III TRIBE and TRIBE2 studies: 1187 pts aged 18–70 years with ECOG performance status (PS) ≤ 2 or between 71–75 years with an ECOG PS of 0 were randomized to receive first-line FOLFOXIRI/bevacizumab or a doublet (FOLFIRI in TRIBE and mFOLFOX6 in TRIBE2)/bevacizumab. Here, we aimed at assessing the effect of the intensification of the upfront chemotherapy (triplet versus doublet) in terms of safety and efficacy in pts aged < 70 versus 70-75. Methods: Subgroup analyses for ORR, PFS, G3/4 overall adverse events (AEs), chemo-related and bevacizumab-related AEs were performed according to baseline age. Results: 182 (15%) out of 1187 pts were 70-75 years old (97 in the FOLFOXIRI/bevacizumab and 85 in the doublets/bevacizumab arms). The benefit provided by the intensification of the upfront chemotherapy was independent of the age subgroup in terms of both ORR (p for interaction = 0.684) and PFS (p for interaction = 0.634). The risk of overall and chemo-related G3/4 AEs was increased with the triplet independently of age (p for interaction = 0.736 and 0.790), while no difference in bevacizumab-related AEs was observed in both subgroups (p for interaction = 0.566). In the overall population, as compared to younger pts, those aged 70-75 were more susceptible to overall G3/4 AEs (70% vs 57%, p = 0.001). In the FOLFOXIRI/bevacizumab arm a higher incidence of G3/4 diarrhea (27% vs 17%, p = 0.016) and febrile neutropenia (16% vs 6% p = 0.001) and a lower incidence of all grade nausea (51% vs 65%, p = 0.009) and vomiting (26% vs 44% p = 0.001) were reported among elderly pts. Conclusions: The activity and efficacy of FOLFOXIRI/bevacizumab are confirmed among selected pts between 70 and 75 years old, with a relative increase in the risk of chemo-related AEs similar to that of younger pts. However, elderly pts are more susceptible to experience AEs independently of the treatment arm. Considering the increased incidence of febrile neutropenia and diarrhea with FOLFOXIRI/bevacizumab, the use of G-CSF as primary prophylaxis or an initial dose reduction of irinotecan and 5-fluorouracil might be considered in this population." @default.
- W2947305026 created "2019-06-07" @default.
- W2947305026 creator A5001295747 @default.
- W2947305026 creator A5009657109 @default.
- W2947305026 creator A5012034272 @default.
- W2947305026 creator A5013554030 @default.
- W2947305026 creator A5015390593 @default.
- W2947305026 creator A5015936724 @default.
- W2947305026 creator A5026460566 @default.
- W2947305026 creator A5030001742 @default.
- W2947305026 creator A5045260424 @default.
- W2947305026 creator A5045419569 @default.
- W2947305026 creator A5051613962 @default.
- W2947305026 creator A5057503389 @default.
- W2947305026 creator A5058657353 @default.
- W2947305026 creator A5066696741 @default.
- W2947305026 creator A5072503801 @default.
- W2947305026 creator A5078836749 @default.
- W2947305026 creator A5080776095 @default.
- W2947305026 creator A5081985776 @default.
- W2947305026 creator A5083540572 @default.
- W2947305026 creator A5090671983 @default.
- W2947305026 date "2019-05-20" @default.
- W2947305026 modified "2023-09-23" @default.
- W2947305026 title "Impact of age on safety and efficacy of first-line FOLFOXIRI/bevacizumab in mCRC: A pooled analysis of TRIBE and TRIBE2 studies." @default.
- W2947305026 doi "https://doi.org/10.1200/jco.2019.37.15_suppl.3536" @default.
- W2947305026 hasPublicationYear "2019" @default.
- W2947305026 type Work @default.
- W2947305026 sameAs 2947305026 @default.
- W2947305026 citedByCount "0" @default.
- W2947305026 crossrefType "journal-article" @default.
- W2947305026 hasAuthorship W2947305026A5001295747 @default.
- W2947305026 hasAuthorship W2947305026A5009657109 @default.
- W2947305026 hasAuthorship W2947305026A5012034272 @default.
- W2947305026 hasAuthorship W2947305026A5013554030 @default.
- W2947305026 hasAuthorship W2947305026A5015390593 @default.
- W2947305026 hasAuthorship W2947305026A5015936724 @default.
- W2947305026 hasAuthorship W2947305026A5026460566 @default.
- W2947305026 hasAuthorship W2947305026A5030001742 @default.
- W2947305026 hasAuthorship W2947305026A5045260424 @default.
- W2947305026 hasAuthorship W2947305026A5045419569 @default.
- W2947305026 hasAuthorship W2947305026A5051613962 @default.
- W2947305026 hasAuthorship W2947305026A5057503389 @default.
- W2947305026 hasAuthorship W2947305026A5058657353 @default.
- W2947305026 hasAuthorship W2947305026A5066696741 @default.
- W2947305026 hasAuthorship W2947305026A5072503801 @default.
- W2947305026 hasAuthorship W2947305026A5078836749 @default.
- W2947305026 hasAuthorship W2947305026A5080776095 @default.
- W2947305026 hasAuthorship W2947305026A5081985776 @default.
- W2947305026 hasAuthorship W2947305026A5083540572 @default.
- W2947305026 hasAuthorship W2947305026A5090671983 @default.
- W2947305026 hasConcept C126322002 @default.
- W2947305026 hasConcept C143998085 @default.
- W2947305026 hasConcept C144024400 @default.
- W2947305026 hasConcept C19165224 @default.
- W2947305026 hasConcept C2776694085 @default.
- W2947305026 hasConcept C2777802072 @default.
- W2947305026 hasConcept C2779121571 @default.
- W2947305026 hasConcept C2993493390 @default.
- W2947305026 hasConcept C3017976582 @default.
- W2947305026 hasConcept C556039675 @default.
- W2947305026 hasConcept C71924100 @default.
- W2947305026 hasConceptScore W2947305026C126322002 @default.
- W2947305026 hasConceptScore W2947305026C143998085 @default.
- W2947305026 hasConceptScore W2947305026C144024400 @default.
- W2947305026 hasConceptScore W2947305026C19165224 @default.
- W2947305026 hasConceptScore W2947305026C2776694085 @default.
- W2947305026 hasConceptScore W2947305026C2777802072 @default.
- W2947305026 hasConceptScore W2947305026C2779121571 @default.
- W2947305026 hasConceptScore W2947305026C2993493390 @default.
- W2947305026 hasConceptScore W2947305026C3017976582 @default.
- W2947305026 hasConceptScore W2947305026C556039675 @default.
- W2947305026 hasConceptScore W2947305026C71924100 @default.
- W2947305026 hasLocation W29473050261 @default.
- W2947305026 hasOpenAccess W2947305026 @default.
- W2947305026 hasPrimaryLocation W29473050261 @default.
- W2947305026 hasRelatedWork W2075229757 @default.
- W2947305026 hasRelatedWork W2165180460 @default.
- W2947305026 hasRelatedWork W2277248114 @default.
- W2947305026 hasRelatedWork W2343019521 @default.
- W2947305026 hasRelatedWork W2539314953 @default.
- W2947305026 hasRelatedWork W2597629258 @default.
- W2947305026 hasRelatedWork W2602047069 @default.
- W2947305026 hasRelatedWork W2612453093 @default.
- W2947305026 hasRelatedWork W2622186675 @default.
- W2947305026 hasRelatedWork W2736995408 @default.
- W2947305026 hasRelatedWork W2749779586 @default.
- W2947305026 hasRelatedWork W2791470764 @default.
- W2947305026 hasRelatedWork W2809029813 @default.
- W2947305026 hasRelatedWork W2921123888 @default.
- W2947305026 hasRelatedWork W2946920613 @default.
- W2947305026 hasRelatedWork W2956970956 @default.
- W2947305026 hasRelatedWork W2971389827 @default.
- W2947305026 hasRelatedWork W3030739193 @default.
- W2947305026 hasRelatedWork W3176637673 @default.
- W2947305026 hasRelatedWork W3198422742 @default.
- W2947305026 isParatext "false" @default.
- W2947305026 isRetracted "false" @default.
- W2947305026 magId "2947305026" @default.
- W2947305026 workType "article" @default.